Vaccinations in Infants Born Preterm: An Update

Author(s): Areti Aphrodite Sioriki, Despoina Gkentzi, Evangelia Papadimitriou, Gabriel Dimitriou, Ageliki Karatza*

Journal Name: Current Pediatric Reviews

Volume 16 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Infants born prematurely (before completion of 37 weeks of gestation) are at increased risk of morbidity and mortality due to vaccine preventable diseases, mostly because of their immunological immaturity and failure of transfer of maternal protective antibodies. Despite their great need of being vaccinated, concerns on vaccine safety and efficacy, constitute the main reasons for which vaccinations are often delayed in this group. In this review we summarize the latest evidence on vaccine safety, efficacy and immunogenicity in preterm infants which is similar to full-term infants. Therefore there is no reason for delaying vaccination in this population.

Keywords: Vaccinations, immunization, premature infants, born, morbidity, mortality, immunogenicity.

[1]
Harrison MS, Goldenberg RL. Global burden of prematurity. Semin Fetal Neonatal Med 2016; 21(2): 74-9.
[http://dx.doi.org/10.1016/j.siny.2015.12.007] [PMID: 26740166]
[2]
Blencowe H, Cousens S, Chou D, et al. Born Too Soon Preterm Birth Action Group. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health 2013; 10(Suppl. 1): S2.
[http://dx.doi.org/10.1186/1742-4755-10-S1-S2] [PMID: 24625129]
[3]
Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Semin Perinatol 2017; 41(7): 387-91.
[http://dx.doi.org/10.1053/j.semperi.2017.07.009] [PMID: 28865982]
[5]
The Immunisation Advisory Centre [Home page on the Internet] Immunisationfor the low birth weight and/or preterm infant. (Updated September 2017). Available from: http://www.immune.org.nz/sites/default/files/resources/Written%20Resources/AdministrationPretermLowBirthWgtImac20170918V01Final.pdf
[6]
Esposito S, Serra D, Gualtieri L, Cesati L, Principi N. Vaccines and preterm neonates: why, when, and with what. Early Hum Dev 2009; 85(10)(Suppl.): S43-5.
[http://dx.doi.org/10.1016/j.earlhumdev.2009.08.011] [PMID: 19775838]
[7]
Gagneur A, Pinquier D, Quach C. Immunization of preterm infants. Hum Vaccin Immunother 2015; 11(11): 2556-63.
[http://dx.doi.org/10.1080/21645515.2015.1074358] [PMID: 26291883]
[8]
Bonhoeffer J, Siegrist CA, Heath PT. Immunisation of premature infants. Arch Dis Child 2006; 91(11): 929-35.
[http://dx.doi.org/10.1136/adc.2005.086306] [PMID: 17056868]
[9]
Sharma AA, Jen R, Butler A, Lavoie PM. The developing human preterm neonatal immune system: a case for more research in this area. Clin Immunol 2012; 145(1): 61-8.
[http://dx.doi.org/10.1016/j.clim.2012.08.006] [PMID: 22926079]
[10]
Esposito S, Pugni L, Mosca F, Principi N. Rotarix® and RotaTeq® administration to preterm infants in the neonatal intensive care unit: Review of available evidence. Vaccine 2018; 36(36): 5430-4.
[http://dx.doi.org/10.1016/j.vaccine.2017.10.013] [PMID: 29037579]
[11]
Czajka H, Lauterbach R, Pawlik D. Vaccination of preterm infants by polyvalent vaccines: immunogenicity and safety- review of literature. Dev Period Med 2014; 18(3): 360-6.
[PMID: 25182401]
[12]
Resch B. Vaccination of Preterm Infants. J Neonatal Biol 2014; 3(1)e107
[http://dx.doi.org/10.4172/2167-0897.1000e107]
[13]
Woestenberg PJ, van Lier A, van der Maas NAT, Drijfhout IH, Oomen PJ, de Melker HE. Delayed start of diphtheria, tetanus, acellular pertussis and inactivated polio vaccination in preterm and low birth weight infants in the Netherlands. Pediatr Infect Dis J 2014; 33(2): 190-8.
[http://dx.doi.org/10.1097/INF.0000000000000106] [PMID: 24168985]
[14]
Omeñaca F, Vázquez L, Garcia-Corbeira P, et al. Immunization of preterm infants with GSK’s hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Vaccine 2018; 36(7): 986-96.
[http://dx.doi.org/10.1016/j.vaccine.2018.01.005] [PMID: 29336924]
[15]
Ugazio AG, Tozzi AE. Vaccinations and Neonatal ImmunityNeonatology Milano. Springer 2012; pp. 944-8.
[http://dx.doi.org/10.1007/978-88-470-1405-3_119]
[16]
Slack MH, Cade S, Schapira D, et al. DT5aP-Hib-IPV and MCC vaccines: preterm infants’ response to accelerated immunisation. Arch Dis Child 2005; 90(4): 338-41.
[http://dx.doi.org/10.1136/adc.2004.052720] [PMID: 15781918]
[17]
Gkentzi D, Katsakiori P, Marangos M, et al. Maternal vaccination against pertussis: a systematic review of the recent literature. Arch Dis Child Fetal Neonatal Ed 2017; 102(5): F456-63.
[http://dx.doi.org/10.1136/archdischild-2016-312341] [PMID: 28468899]
[18]
Eberhardt CS, Blanchard-Rohner G, Lemaître B, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 2016; 62(7): 829-36.
[http://dx.doi.org/10.1093/cid/ciw027] [PMID: 26797213]
[20]
Waitz M, Hopfner R, Hummler HD, Heininger U, Hepatitis B, Hepatitis B. Postexposure Prophylaxis in Preterm and Low-Birth-Weight Infants. AJP Rep 2015; 5(1): e67-72.
[PMID: 26199803]
[21]
Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999; 103(2)E14
[http://dx.doi.org/10.1542/peds.103.2.e14] [PMID: 9925860]
[22]
Gad A, Shah S. Special immunization considerations of the preterm infant. J Pediatr Health Care 2007; 21(6): 385-91.
[http://dx.doi.org/10.1016/j.pedhc.2007.05.005] [PMID: 17980805]
[23]
Tavares EC, Ribeiro JG, Oliveira LA. Active and passive immunization in the extremely preterm infant. J Pediatr (Rio J) 2005; 81(1)(Suppl.): S89-94.
[http://dx.doi.org/10.2223/1307] [PMID: 15809702]
[24]
Tan CXT, Chan SM, Lee LY, et al. Serologic responses after hepatitis B vaccination in preterm infants born to hepatitis B surface antigen-positive mothers: Singapore experience. Pediatr Infect Dis J 2017; 36(8): e208-10.
[http://dx.doi.org/10.1097/INF.0000000000001578] [PMID: 28198787]
[25]
David W, Kimberlin DW, Brady MT, Jackson MA, Long SS, Eds. Committee on Infectious Diseases, American Academy of Pediatrics Red book : 2015 Report of the Committee on Infectious Diseases. Elk GroveVillage, IL: American Academy of Pediatrics 2015.
[26]
Kent A, Ladhani SN, Andrews NJ, et al. PUNS Study Group. Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT. Pediatrics 2016; 138(3)e20153945
[http://dx.doi.org/10.1542/peds.2015-3945] [PMID: 27503351]
[27]
Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 2002; 21(3): 182-6.
[http://dx.doi.org/10.1097/00006454-200203000-00003] [PMID: 12005078]
[28]
Martinón-Torres F, Czajka H, Center KJ, et al. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics 2015; 135(4): e876-86.
[http://dx.doi.org/10.1542/peds.2014-2941] [PMID: 25780077]
[29]
Sawyer MH, Rathore M. Pneumococcal vaccines in preterm infants: are more doses better? implications for other vaccines. Pediatrics 2016; 138(3)e20160975
[http://dx.doi.org/10.1542/peds.2016-0975] [PMID: 27503350]
[30]
Martinón-Torres F, Wysocki J, Center KJ, et al. Circulating antibody 1 and 2 years after vaccination with the 13-valent pneumococcal conjugate vaccine in preterm compared with term infants. Pediatr Infect Dis J 2017; 36(3): 326-32.
[http://dx.doi.org/10.1097/INF.0000000000001428] [PMID: 27902652]
[31]
Collins CL, Ruggeberg JU, Balfour G, et al. Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants. Pediatr Infect Dis J 2005; 24(11): 966-8.
[http://dx.doi.org/10.1097/01.inf.0000187027.45918.6a] [PMID: 16282930]
[32]
Clarke P, Robinson MJ, Ahmad I, et al. Response of steroid-treated former preterm infants to a single dose of meningococcal C conjugate vaccine. Vaccine 2006; 24(16): 3273-8.
[http://dx.doi.org/10.1016/j.vaccine.2006.01.027] [PMID: 16472548]
[33]
Slack MH, Schapira D, Thwaites RJ, et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis 2001; 184(12): 1617-20.
[http://dx.doi.org/10.1086/324666] [PMID: 11740740]
[34]
Esposito S, Corbellini B, Bosis S, et al. Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 2007; 25(26): 4889-94.
[http://dx.doi.org/10.1016/j.vaccine.2007.04.018] [PMID: 17513025]
[35]
Slack MH, Schapira D, Thwaites RJ, et al. Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal Neonatal Ed 2004; 89(3): F269-71.
[http://dx.doi.org/10.1136/adc.2003.030718] [PMID: 15102734]
[36]
Roué JM, Nowak E, Le Gal G, et al. Impact of rotavirus vaccine on premature infants. Clin Vaccine Immunol 2014; 21(10): 1404-9.
[http://dx.doi.org/10.1128/CVI.00265-14] [PMID: 25080553]
[37]
Ladhani SN, Ramsay ME. Timely immunisation of premature infants against rotavirus in the neonatal intensive care unit. Arch Dis Child Fetal Neonatal Ed 2014; 99(6): F445-7.
[http://dx.doi.org/10.1136/archdischild-2013-305744] [PMID: 25053636]
[38]
Crawford NW, Hunt RW. Rotavirus vaccine timeliness in special care nurseries. Arch Dis Child Fetal Neonatal Ed 2014; 99(3): F251-2.
[http://dx.doi.org/10.1136/archdischild-2014-306107] [PMID: 24596405]
[39]
Monk HM, Motsney AJ, Wade KC. Safety of rotavirus vaccine in the NICU. Pediatrics 2014; 133(6): e1555-60.
[http://dx.doi.org/10.1542/peds.2013-3504] [PMID: 24843056]
[40]
Smith CK, McNeal MM, Meyer NR, Haase S, Dekker CL. Rotavirus shedding in premature infants following first immunization. Vaccine 2011; 29(45): 8141-6.
[http://dx.doi.org/10.1016/j.vaccine.2011.08.028] [PMID: 21856359]
[41]
Omenaca F, Sarlangue J, Szenborn L, et al. ROTA-054 Study Group Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012; 31(5): 487-93.
[http://dx.doi.org/10.1097/INF.0b013e3182490a2c] [PMID: 22228231]
[43]
D’Angio CT, Heyne RJ, Duara S, et al. Premature Infant Vaccine Collaborative Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. Pediatr Infect Dis J 2011; 30(7): 570-4.
[http://dx.doi.org/10.1097/INF.0b013e31820c1fdf] [PMID: 21273938]
[44]
D’Angio CT, Wyman CP, Misra RS, et al. Plasma cell and serum antibody responses to influenza vaccine in preterm and full-term infants. Vaccine 2017; 35(38): 5163-71.
[http://dx.doi.org/10.1016/j.vaccine.2017.07.115] [PMID: 28807607]
[45]
D’Angio CT, Boohene PA, Mowrer A, et al. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants. Pediatrics 2007; 119(3): e574-9.
[http://dx.doi.org/10.1542/peds.2006-2241] [PMID: 17332177]
[46]
Ferreira CSM, Perin MCAA, Moraes-Pinto MI, et al. Humoral immune response to measles and varicella vaccination in former very low birth weight preterm infants. Braz J Infect Dis 2018; 22(1): 41-6.
[http://dx.doi.org/10.1016/j.bjid.2017.12.001] [PMID: 29306654]
[47]
Sadarangani M, Barlow S, Anthony M, Pollard AJ. Four Component Meningococcal Capsular Group B Vaccine in Preterm Infants. J Pediatric Infect Dis Soc 2017; 6(3): 309-10.
[http://dx.doi.org/10.1093/jpids/pix013] [PMID: 28369464]
[48]
Kent A, Beebeejaun K, Braccio S, et al. National Neonatal Audit Network. Safety of meningococcal group B vaccination in hospitalised premature infants. Arch Dis Child Fetal Neonatal Ed 2019; 104(2): F171-5.
[http://dx.doi.org/10.1136/archdischild-2017-314152] [PMID: 29636385]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [148 - 155]
Pages: 8
DOI: 10.2174/1573396316666200116094459

Article Metrics

PDF: 36
HTML: 3